Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
Immunovia will present updates on its next-generation pancreatic cancer detection test at the annual PRECEDE Consortium meeting. The test showed 85% sensitivity and 98% specificity in a model-development study of 623 patient samples. The PRECEDE Consortium, comprising 51 pancreatic centers worldwide, aims to increase five-year survival rates to 50% through early detection research. The consortium has enrolled over 7,000 of its targeted 10,000 high-risk patients. Immunovia plans to complete clinical validation in December 2024 and launch the test in 2025.
Immunovia presenterà aggiornamenti sul suo test di rilevamento del cancro pancreatico di nuova generazione durante l'incontro annuale del Consorzio PRECEDE. Il test ha mostrato una sensibilità dell'85% e una specificità del 98% in uno studio di sviluppo del modello su 623 campioni di pazienti. Il Consorzio PRECEDE, composto da 51 centri pancreatici in tutto il mondo, mira ad aumentare i tassi di sopravvivenza a cinque anni al 50% attraverso la ricerca sulla rilevazione precoce. Il consorzio ha arruolato oltre 7.000 dei 10.000 pazienti ad alto rischio previsti. Immunovia prevede di completare la validazione clinica entro dicembre 2024 e lanciare il test nel 2025.
Immunovia presentará actualizaciones sobre su prueba de detección de cáncer de páncreas de nueva generación en la reunión anual del Consorcio PRECEDE. La prueba mostró una sensibilidad del 85% y una especificidad del 98% en un estudio de desarrollo de modelo con 623 muestras de pacientes. El Consorcio PRECEDE, que incluye 51 centros pancreáticos en todo el mundo, tiene como objetivo aumentar las tasas de supervivencia a cinco años al 50% mediante la investigación en detección temprana. El consorcio ha inscrito a más de 7,000 de los 10,000 pacientes de alto riesgo previstos. Immunovia planea completar la validación clínica en diciembre de 2024 y lanzar la prueba en 2025.
이뮤노비아는 연례 프리시드 컨소시엄 회의에서 차세대 췌장암 검출 테스트에 대한 업데이트를 발표할 예정입니다. 이 테스트는 623명의 환자 샘플을 통한 모델 개발 연구에서 85%의 민감도와 98%의 특이성을 보였습니다. 전 세계 51개의 췌장 센터로 구성된 프리시드 컨소시엄은 조기 검출 연구를 통해 5년 생존율을 50%로 높이는 것을 목표로 하고 있습니다. 컨소시엄은 목표 10,000명의 고위험 환자 중 7,000명 이상을 등록했습니다. 이뮤노비아는 2024년 12월까지 임상 검증을 완료하고 2025년에 테스트를 출시할 계획입니다.
Immunovia présentera des mises à jour sur son test de détection du cancer du pancréas de nouvelle génération lors de la réunion annuelle du Consortium PRECEDE. Le test a montré une sensibilité de 85 % et une spécificité de 98 % dans une étude de développement de modèle portant sur 623 échantillons de patients. Le Consortium PRECEDE, qui regroupe 51 centres pancréatiques à travers le monde, vise à augmenter les taux de survie à cinq ans à 50 % grâce à la recherche sur la détection précoce. Le consortium a enrôlé plus de 7 000 des 10 000 patients à haut risque ciblés. Immunovia prévoit de compléter la validation clinique d'ici décembre 2024 et de lancer le test en 2025.
Immunovia wird beim jährlichen Treffen des PRECEDE-Konsortiums Neuigkeiten zu seinem nächsten Generationstest zur Erkennung von Bauchspeicheldrüsenkrebs präsentieren. Der Test zeigte in einer Studienentwicklung mit 623 Patientenproben eine Empfindlichkeit von 85% und eine Spezifität von 98%. Das PRECEDE-Konsortium, das aus 51 Bauchspeicheldrüsenzentren weltweit besteht, hat sich zum Ziel gesetzt, die Fünf-Jahres-Überlebensrate durch Früherkennungsforschung auf 50% zu steigern. Das Konsortium hat über 7.000 der anvisierten 10.000 Hochrisikopatienten eingeschrieben. Immunovia plant, die klinische Validierung bis Dezember 2024 abzuschließen und den Test im Jahr 2025 auf den Markt zu bringen.
- Strong test performance metrics with 85% sensitivity and 98% specificity
- Collaboration with major research consortium (51 centers) strengthening clinical validation
- Clear timeline for product launch in 2025
- Product launch not expected until late 2025
- Clinical validation study still pending completion
Insights
The presentation of Immunovia's next-generation pancreatic cancer detection test shows promising clinical results with
The collaboration with PRECEDE Consortium, encompassing 51 pancreatic centers and over 7,000 enrolled patients, provides robust validation opportunities and access to valuable blood samples for clinical studies. The planned commercial launch in 2025, following the completion of clinical validation in December 2024, represents a significant milestone in addressing the unmet need for early pancreatic cancer detection in the 1.8 million high-risk individuals in the US market alone.
Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation. As reported in a 1 August 2024 press release, the test demonstrated superior performance, with sensitivity of
The annual meeting of the PRECEDE Consortium will bring together pancreatic cancer experts for two days of informational panels, partner updates, collaboration, and information sharing. Founded in 2020, the international PRECEDE Study is open to individuals with a family history of pancreatic cancer and/or those who carry genetic variants linked to development of the cancer. The PRECEDE Consortium's ambitious goal is to increase the five-year survival rate to
"Our collaboration with PRECEDE has proven tremendously valuable. PRECEDE researchers provided hundreds of blood samples to support the current clinical validation study of our next-generation test," said Jeff Borcherding, Chief Executive Officer at Immunovia. He continued, "We are excited to update Consortium members and discuss ways we can collaborate to generate additional data on the accuracy and clinical use of our test. It's energizing to partner with a group that is so passionate about improving pancreatic cancer survival through early detection."
As communicated previously, Immunovia expects to complete the clinical validation study in December 2024 in preparation for launching its next-generation test for early detection of pancreatic cancer later in 2025.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist-Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
CONTACT:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-presents-data-from-model-development-study-at-meeting-of-the-precede-pancreatic-cancer-research-consortium-302298871.html
SOURCE Immunovia AB
FAQ
What are the performance metrics of Immunovia's (IMMNOV) new pancreatic cancer test?
When will Immunovia (IMMNOV) launch its next-generation pancreatic cancer test?
How many centers are involved in the PRECEDE Consortium working with Immunovia (IMMNOV)?
